Current Report Filing (8-k)
November 04 2016 - 9:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
November 4, 2016
Date of report (Date of earliest event reported)
Nexvet
Biopharma
public limited company
(Exact Name of Registrant as Specified in Its Charter)
|
|
|
|
|
Ireland
|
|
001-36828
|
|
98-1205017
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98, Ireland
(Address of principal executive offices, including zip code)
+353 5793 24522
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On November 4, 2016, Nexvet Biopharma public
limited company (the Company) reported its financial results for the first quarter of fiscal year 2017 (the quarterly period ended September 30, 2016). The Companys earnings release for this period is furnished herewith as
Exhibit 99.1.
Item 9.01
|
Financial Statements and Exhibits.
|
|
|
|
Exhibit
|
|
Description
|
|
|
99.1
|
|
Earnings release dated November 4, 2016 announcing the Companys financial results for the first quarter of fiscal year 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
Nexvet Biopharma public limited company
|
|
|
By:
|
|
/s/ Mark Heffernan, Ph.D.
|
Name:
|
|
Mark Heffernan
|
Its:
|
|
Chief Executive Officer
|
Date: November 4, 2016
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Aug 2024 to Sep 2024
NEXVET BIOPHARMA PLC (NASDAQ:NVET)
Historical Stock Chart
From Sep 2023 to Sep 2024